JPWO2020076789A5 - - Google Patents

Info

Publication number

JPWO2020076789A5

JPWO2020076789A5 JP2021519612A JP2021519612A JPWO2020076789A5 JP WO2020076789 A5 JPWO2020076789 A5 JP WO2020076789A5 JP 2021519612 A JP2021519612 A JP 2021519612A JP 2021519612 A JP2021519612 A JP 2021519612A JP WO2020076789 A5 JPWO2020076789 A5 JP WO2020076789A5

Authority

JP

Japan

Prior art keywords

antigen

antibody

aureus

binding fragment

binds

Prior art date

2022-10-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims description 362
• 108091007433 antigens Proteins 0.000 claims description 362
• 102000036639 antigens Human genes 0.000 claims description 362
• 239000012634 fragment Substances 0.000 claims description 362
• 239000000203 mixture Substances 0.000 claims description 112
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 95
• 101710092462 Alpha-hemolysin Proteins 0.000 claims description 92
• 101710197219 Alpha-toxin Proteins 0.000 claims description 92
• 101710124951 Phospholipase C Proteins 0.000 claims description 92
• 239000002776 alpha toxin Substances 0.000 claims description 92
• 101710198480 Clumping factor A Proteins 0.000 claims description 66
• FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 claims description 55
• 101710170970 Leukotoxin Proteins 0.000 claims description 55
• 208000015181 infectious disease Diseases 0.000 claims description 54
• 239000008194 pharmaceutical composition Substances 0.000 claims description 43
• 208000008960 Diabetic foot Diseases 0.000 claims description 19
• 108060003951 Immunoglobulin Proteins 0.000 claims description 11
• 102000018358 immunoglobulin Human genes 0.000 claims description 11
• 230000035772 mutation Effects 0.000 claims description 11
• 206010012601 diabetes mellitus Diseases 0.000 claims description 10
• 230000002401 inhibitory effect Effects 0.000 claims description 9
• 206010035664 Pneumonia Diseases 0.000 claims description 8
• 239000003814 drug Substances 0.000 claims description 8
• 230000002458 infectious effect Effects 0.000 claims description 8
• 206010031252 Osteomyelitis Diseases 0.000 claims description 7
• 206010062255 Soft tissue infection Diseases 0.000 claims description 7
• 206010060968 Arthritis infective Diseases 0.000 claims description 6
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 6
• 206010040047 Sepsis Diseases 0.000 claims description 6
• 208000031729 Bacteremia Diseases 0.000 claims description 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
• 208000031650 Surgical Wound Infection Diseases 0.000 claims description 4
• 206010048038 Wound infection Diseases 0.000 claims description 4
• 238000004220 aggregation Methods 0.000 claims description 4
• 230000002776 aggregation Effects 0.000 claims description 4
• 230000003115 biocidal effect Effects 0.000 claims description 4
• 210000003141 lower extremity Anatomy 0.000 claims description 4
• 210000000988 bone and bone Anatomy 0.000 claims description 3
• 206010040872 skin infection Diseases 0.000 claims description 3
• 239000003053 toxin Substances 0.000 claims description 3
• 231100000765 toxin Toxicity 0.000 claims description 3
• 241000191967 Staphylococcus aureus Species 0.000 claims description 2
• 230000015572 biosynthetic process Effects 0.000 claims description 2
• 230000003628 erosive effect Effects 0.000 claims description 2
• 230000001939 inductive effect Effects 0.000 claims description 2
• 230000003902 lesion Effects 0.000 claims description 2
• 230000001662 opsonic effect Effects 0.000 claims description 2
• 230000009424 thromboembolic effect Effects 0.000 claims description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 206010064687 Device related infection Diseases 0.000 claims 2
• 208000011354 prosthesis-related infectious disease Diseases 0.000 claims 2
• 229940072221 immunoglobulins Drugs 0.000 claims 1
• 238000006386 neutralization reaction Methods 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 149
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 102000008946 Fibrinogen Human genes 0.000 description 3
• 108010049003 Fibrinogen Proteins 0.000 description 3
• 229940012952 fibrinogen Drugs 0.000 description 3
• 238000003556 assay Methods 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 101100523490 Dictyostelium discoideum rab8A gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 108010068617 neonatal Fc receptor Proteins 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1